96 related articles for article (PubMed ID: 22384858)
21. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
[TBL] [Abstract][Full Text] [Related]
22. Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.
Ohgami T; Kato K; Kobayashi H; Sonoda K; Inoue T; Yamaguchi S; Yoneda T; Wake N
Cancer Sci; 2010 Jun; 101(6):1387-95. PubMed ID: 20331637
[TBL] [Abstract][Full Text] [Related]
23. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
24. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
[TBL] [Abstract][Full Text] [Related]
25. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
Park EJ; Choi KS; Yoo YH; Kwon TK
Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
[TBL] [Abstract][Full Text] [Related]
26. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological activation of the p53 pathway in haematological malignancies.
Saha MN; Micallef J; Qiu L; Chang H
J Clin Pathol; 2010 Mar; 63(3):204-9. PubMed ID: 19955555
[TBL] [Abstract][Full Text] [Related]
28. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
[TBL] [Abstract][Full Text] [Related]
29. Wilms' tumor gene 1 enhances nutlin-3-induced apoptosis.
Lee SY; Choe YJ; Park JY; Lee SS; Kim YH; Shin SJ; Chung YJ; Kim HS
Oncol Rep; 2014 Jan; 31(1):131-6. PubMed ID: 24190574
[TBL] [Abstract][Full Text] [Related]
30. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.
Ji Z; Njauw CN; Taylor M; Neel V; Flaherty KT; Tsao H
J Invest Dermatol; 2012 Feb; 132(2):356-64. PubMed ID: 21993556
[TBL] [Abstract][Full Text] [Related]
31. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
32. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
[TBL] [Abstract][Full Text] [Related]
33. Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome.
Marks DI; Vonderheid EC; Kurz BW; Bigler RD; Sinha K; Morgan DA; Sukman A; Nowell PC; Haines DS
Br J Haematol; 1996 Mar; 92(4):890-9. PubMed ID: 8616082
[TBL] [Abstract][Full Text] [Related]
34. Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors.
Aizu W; Belinsky GS; Flynn C; Noonan EJ; Boes CC; Godman CA; Doshi B; Nambiar PR; Rosenberg DW; Giardina C
Biochem Pharmacol; 2006 Oct; 72(8):981-91. PubMed ID: 16949053
[TBL] [Abstract][Full Text] [Related]
35. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P
J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964
[TBL] [Abstract][Full Text] [Related]
36. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
38. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
39. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
40. TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.
Gros A; Laharanne E; Vergier M; Prochazkova-Carlotti M; Pham-Ledard A; Bandres T; Poglio S; Berhouet S; Vergier B; Vial JP; Chevret E; Beylot-Barry M; Merlio JP
PLoS One; 2017; 12(3):e0173171. PubMed ID: 28301507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]